SELLAS Life Sciences Group, Inc.
Stacy Y. has a diverse work experience in the legal field. Stacy most recently worked as an Associate General Counsel at SELLAS Life Sciences Group, Inc. starting in September 2022. Prior to this, Stacy held the position of Assistant General Counsel at Arena Pharmaceuticals, Inc. from September 2020 to August 2022, where they managed global litigation and claims for the company. Before that, they served as Deputy General Counsel at DBV Technologies from June 2019 to September 2020, reporting directly to the Chief Legal Officer.
Stacy also has experience at Bayer, where they held the role of Senior Counsel and Senior Assistant General Counsel from October 2016 to May 2019. Stacy was responsible for providing legal guidance on compliance, marketing, and sales materials for well-known brands and potential products within the Consumer Health Division. Stacy also acted as the legal lead for Rx-to-OTC Switch, evaluating legal pathways and potential business opportunities. Prior to this, they worked as Counsel II in the Consumer Health Division at Bayer from November 2015 to October 2016.
Earlier in their career, Stacy worked as a Senior Associate at Smith Gambrell Russell from 2010 to 2015, specializing in commercial litigation for pharmaceutical and consumer product companies. Stacy appeared before various courts and arbitration panels and second-chaired several trials and arbitrations.
Before joining Smith Gambrell Russell, Stacy worked at Storch Amini PC as an Associate from 2008 to 2009, handling a range of legal services including drafting pleadings, motions, and settlement agreements. Stacy also worked at DLA Piper as an Associate from 2006 to 2008, focused on commercial litigation for pharmaceutical and food products companies.
Stacy began their legal career as an Assistant Attorney General in the Governmental Affairs Division of the Missouri Attorney General's Office from 2004 to 2006. In this role, they litigated cases before state courts and represented the State of Missouri in appeals. Stacy also served as General Counsel for state professional licensing agencies.
Stacy started their legal career as a Law Clerk at the United States Attorneys' Offices in 2004, where they conducted legal research and drafted motions and briefs for Assistant U.S. Attorneys.
Stacy Y. completed their Bachelor of Arts (BA) degree with Honors at Washington University in St. Louis. Stacy pursued a major in Psychology and had a second major in Business, Economics, and the Law at the Olin School of Business. After this, they attended Washington University in St. Louis School of Law and earned a Juris Doctorate from 2001 to 2004. In 2017, they furthered their education at the University of Notre Dame - Mendoza College of Business by completing the Bayer Senior Managers' Business Management Program.
This person is not in any teams
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences AG is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.The Company’s lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitopeimmunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the number 1 target for immunotherapy. Traditional approaches have not been able to address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies. The company has a close working relationship with MSKCC, who is also a shareholder.The Company plans to initiate a pivotal Phase III study in H1:17 in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM) by H2:17 and is currently conducting Phase I and Phase II studies in ovarian cancer (combination with BMS’s nivolumab (Opdivo®) and multiple myeloma (MM) and will advance additional studies into the clinic. Phase II data in AML and MPM have shown positive safety and survival trends, with median OS in AML of 61.8 months vs. ~12-15 months for best standard treatment and median OS in MPM of 24.8 months vs.16.6 months in the control arm. Further recent data in multiple myeloma has shown an 86% overall survival rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation. The US FDA granted orphan designations and fast track designations for SELLAS WT1 therapy, galinpepimut-S, for AML and MPM and the European EMA granted orphan designation for AML and MPM.Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by an attractive safety profile not found in standard of care therapies.